CY1110074T1 - Ενωσεις βενζιμιδαζολιου - Google Patents

Ενωσεις βενζιμιδαζολιου

Info

Publication number
CY1110074T1
CY1110074T1 CY20101100543T CY101100543T CY1110074T1 CY 1110074 T1 CY1110074 T1 CY 1110074T1 CY 20101100543 T CY20101100543 T CY 20101100543T CY 101100543 T CY101100543 T CY 101100543T CY 1110074 T1 CY1110074 T1 CY 1110074T1
Authority
CY
Cyprus
Prior art keywords
gastric acid
petrol
compounds
inhibitory effect
effect against
Prior art date
Application number
CY20101100543T
Other languages
English (en)
Inventor
Shuhei Miyazawa
Masanobu Shinoda
Tetsuya Kawahara
Nobuhisa Watanabe
Hitoshi Harada
Daisuke Iida
Hiroki Terauchi
Junichi Nagakawa
Hideaki Fujisaki
Atsuhiko Kubota
Masato Ueda
Original Assignee
Eisai R&D Management Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co., Ltd filed Critical Eisai R&D Management Co., Ltd
Publication of CY1110074T1 publication Critical patent/CY1110074T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Αντικείμενο της παρούσας εφεύρεσης είναι να παρέχει μία νέα χημική ένωση χρήσιμη ως θεραπευτικό ή προφυλακτικό παράγοντα για οξεο-συναφείς νόσους, που έχει εξαιρετικό ανασταλτικό αποτέλεσμα έναντι έκκρισης γαστρικού οξέος, εξαιρετικό αποτέλεσμα διατήρησης του ανασταλτικού αποτελέσματος έναντι έκκρισης γαστρικού οξέος, διατηρώντας με τον τρόπο αυτό ενδογαστρικό pΗ υψηλό για μεγάλο χρόνο και που έχει περισσότερο ασφαλή και κατάλληλη φυσικοχημική σταθερότητα. Παρεχόμενη είναι μία ένωση που αντιπροσωπεύεται από
CY20101100543T 2005-04-15 2010-06-11 Ενωσεις βενζιμιδαζολιου CY1110074T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005117643 2005-04-15
US67584805P 2005-04-29 2005-04-29
EP06731998A EP1870409B1 (en) 2005-04-15 2006-04-17 Benzimidazole compounds

Publications (1)

Publication Number Publication Date
CY1110074T1 true CY1110074T1 (el) 2015-01-14

Family

ID=37115157

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100543T CY1110074T1 (el) 2005-04-15 2010-06-11 Ενωσεις βενζιμιδαζολιου

Country Status (23)

Country Link
US (3) US20070015782A1 (el)
EP (1) EP1870409B1 (el)
JP (1) JP4949246B2 (el)
KR (1) KR101285696B1 (el)
AU (1) AU2006237974B2 (el)
BR (1) BRPI0608400B8 (el)
CA (1) CA2602610C (el)
CY (1) CY1110074T1 (el)
DE (1) DE602006014261D1 (el)
DK (1) DK1870409T3 (el)
ES (1) ES2344467T3 (el)
HK (1) HK1117826A1 (el)
HR (1) HRP20100389T1 (el)
IL (1) IL186282A (el)
ME (1) ME01855B (el)
NO (1) NO339502B1 (el)
NZ (1) NZ561920A (el)
PL (1) PL1870409T3 (el)
PT (1) PT1870409E (el)
RS (1) RS51389B (el)
RU (1) RU2409573C2 (el)
SI (1) SI1870409T1 (el)
WO (1) WO2006112442A1 (el)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070015782A1 (en) * 2005-04-15 2007-01-18 Eisai Co., Ltd. Benzimidazole compound
WO2007122686A1 (ja) * 2006-04-14 2007-11-01 Eisai R & D Management Co., Ltd. ベンズイミダゾール化合物
JP5492417B2 (ja) * 2006-10-13 2014-05-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 胃酸分泌抑制作用を有するベンズイミダゾール化合物
JP2009196894A (ja) * 2006-10-13 2009-09-03 Eisai R & D Management Co Ltd スルフィニルベンズイミダゾール化合物またはその塩の製造方法
TWI460182B (zh) * 2007-04-11 2014-11-11 Daiichi Sankyo Co Ltd 原酸酯之製造方法
SI2071986T1 (sl) 2007-12-18 2012-04-30 Nestec Sa Sistem za pripravo napitka iz sestavin, podprt s kodiranim vloĹľkom
EP2588467A1 (en) 2010-07-01 2013-05-08 Amgen Inc. Heterocyclic compounds and their use as inhibitors of pi3k activity
DK2894151T3 (da) 2012-09-04 2021-01-11 Shanghai hengrui pharmaceutical co ltd Imidazolinderivater, fremgangsmåder til fremstilling deraf og anvendelse deraf i medicin
EP2803666B1 (de) 2013-05-17 2016-04-27 Symrise AG Cyclische Acetale und Ketale sowie deren Verwendung als Riechstoff
JP6377334B2 (ja) * 2013-10-25 2018-08-22 東洋鋼鈑株式会社 非線形光学色素、フォトリフラクティブ材料組成物、フォトリフラクティブ基材およびホログラム記録媒体
CN107428726B (zh) * 2014-12-26 2021-03-16 国立大学法人东京大学 光学活性的质子泵抑制剂化合物的制备方法
US10544113B2 (en) 2016-03-07 2020-01-28 National Health Research Institute Thiazolidinone compounds and use thereof
CN112457175B (zh) * 2020-11-03 2022-09-02 山东师范大学 一种制备1,3-二苄氧基-2-丙酮的方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8300736D0 (sv) * 1983-02-11 1983-02-11 Haessle Ab Novel pharmacologically active compounds
EP0187977B1 (en) 1984-12-18 1990-08-29 Otsuka Pharmaceutical Co., Ltd. Tetrahydroquinoline derivatives, process for preparing the same and anti-peptic ulcer compositions containg the same
JPS62277322A (ja) 1986-02-13 1987-12-02 Takeda Chem Ind Ltd 安定化された腸溶性抗潰瘍固形組成物
JPS62207271A (ja) 1986-03-06 1987-09-11 Yamanouchi Pharmaceut Co Ltd ２−ピリジルメチルチオ基または２−ピリジルメチルスルフイニル基で置換された縮合環化合物
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
JPH0643426B2 (ja) 1986-07-25 1994-06-08 東京田辺製薬株式会社 イミダゾ〔４，５−ｂ〕ピリジン誘導体、その製造法及びそれを含有する抗潰瘍剤
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
JPH0222273A (ja) * 1987-07-21 1990-01-25 Yoshitomi Pharmaceut Ind Ltd ピリジン化合物およびその医薬用途
JPH0633261B2 (ja) 1988-01-22 1994-05-02 東京田辺製薬株式会社 新規なイミダゾ［４，５−ｂピリジン誘導体、その製造法及びそれを含有する抗潰瘍剤
SE9002206D0 (sv) * 1990-06-20 1990-06-20 Haessle Ab New compounds
CA2083606C (en) * 1990-06-20 2001-08-21 Arne Elof Brandstrom Dialkoxy-pyridinyl-benzimidazole derivatives, process for their preparation and their pharmaceutical use
JP2820829B2 (ja) 1991-03-07 1998-11-05 武田薬品工業株式会社 有核散剤およびその製造方法
JPH05117268A (ja) * 1991-10-22 1993-05-14 Yoshitomi Pharmaceut Ind Ltd ピリジン化合物
JPH05177268A (ja) 1992-01-09 1993-07-20 Amada Co Ltd 縦型パンチプレス
AU746084B2 (en) 1998-04-17 2002-04-11 Taisho Pharmaceutical Co., Ltd. Multiple-unit sustained release tablets
CN100396675C (zh) 1998-08-10 2008-06-25 加利福尼亚州大学董事会 质子泵抑制剂的前药
TW404832B (en) 1999-01-27 2000-09-11 Nang Kuang Pharmaceutical Co L The oral medicine with good stability cotaining the omeprazole or the analogues
WO2000050037A1 (en) 1999-02-26 2000-08-31 Nitromed, Inc. Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use
US6852739B1 (en) 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
ES2168043B1 (es) 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
US20020064555A1 (en) * 2000-09-29 2002-05-30 Dan Cullen Proton pump inhibitor formulation
JP4331930B2 (ja) 2001-10-17 2009-09-16 武田薬品工業株式会社 酸に不安定な薬物の高含量顆粒
PT2258351E (pt) 2001-10-17 2013-07-29 Takeda Pharmaceutical Grânulos contendo lansoprazole em grande quantidade
JP2003137771A (ja) 2001-10-30 2003-05-14 Nichiko Pharmaceutical Co Ltd 難溶性薬物用医薬製剤
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
US20040166162A1 (en) 2003-01-24 2004-08-26 Robert Niecestro Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
CA2518780C (en) * 2003-03-12 2014-05-13 Takeda Pharmaceutical Company Limited Drug composition having active ingredient adhered at high concentration to spherical core
US20060165793A1 (en) 2003-08-04 2006-07-27 Koji Ukai Pharmaceutical preparation to be dispersed before administration
US20070015782A1 (en) * 2005-04-15 2007-01-18 Eisai Co., Ltd. Benzimidazole compound

Also Published As

Publication number Publication date
RS51389B (en) 2011-02-28
BRPI0608400B1 (pt) 2020-05-05
EP1870409B1 (en) 2010-05-12
DE602006014261D1 (en) 2010-06-24
KR101285696B1 (ko) 2013-07-12
NO339502B1 (no) 2016-12-19
NO20075904L (no) 2007-11-15
HRP20100389T1 (hr) 2010-08-31
WO2006112442A1 (ja) 2006-10-26
BRPI0608400A2 (pt) 2010-11-16
ME01855B (me) 2011-02-28
IL186282A (en) 2014-05-28
US20090203911A1 (en) 2009-08-13
HK1117826A1 (en) 2009-01-23
RU2007138053A (ru) 2009-05-20
US20070010542A1 (en) 2007-01-11
BRPI0608400B8 (pt) 2021-05-25
RU2409573C2 (ru) 2011-01-20
DK1870409T3 (da) 2010-08-09
EP1870409A1 (en) 2007-12-26
US8124780B2 (en) 2012-02-28
PT1870409E (pt) 2010-06-22
NZ561920A (en) 2010-01-29
EP1870409A4 (en) 2009-09-23
KR20070120531A (ko) 2007-12-24
PL1870409T3 (pl) 2010-10-29
AU2006237974A1 (en) 2006-10-26
IL186282A0 (en) 2008-01-20
JPWO2006112442A1 (ja) 2008-12-11
AU2006237974B2 (en) 2011-07-07
JP4949246B2 (ja) 2012-06-06
ES2344467T3 (es) 2010-08-27
CA2602610A1 (en) 2006-10-26
SI1870409T1 (sl) 2010-08-31
CA2602610C (en) 2013-01-22
US7425634B2 (en) 2008-09-16
US20070015782A1 (en) 2007-01-18

Similar Documents

Publication Publication Date Title
CY1110074T1 (el) Ενωσεις βενζιμιδαζολιου
CY1119669T1 (el) Παραγωγα 1-φαινυλ-2-πυριδινυλ-αλκυλ-αλκοολων ως αναστολεις φωσφοδιεστερασης
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
EA201170872A1 (ru) Ингибиторы протеинкиназы
EA200900798A1 (ru) Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы
SMAP200900013A (it) Peptidomimetici smac utili come inibitori di iap
DK1853602T3 (da) Kemiske forbindelser
CY1108275T1 (el) Χημικες ενωσεις
EA201000050A1 (ru) Замещенные бициклолактамные соединения
ECSP066893A (es) Inhibidores de proteínas de apoptosis (iap)
NO20065148L (no) Monocykliske heterocykler som kinase inhibitorer
WO2006123113A3 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
EA200801199A1 (ru) Ингибиторы киназы
EA201390609A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
EA201070786A1 (ru) Бензофуропиримидиноны
WO2009051670A3 (en) Oxylipin compounds for the treatment of ophthalmic conditions
EA200801362A1 (ru) Пиримидинил бензотиофеновые соединения
ECSP088561A (es) Derivados de pirimidinil-aril-urea que son inhibidores de fgf
NO20060202L (no) Pyrrolodihydroisokinoliner som PDE-10-inhibitorer
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
CL2008001705A1 (es) Compuestos derivados de heterociclos de nitrogeno; y uso del compuesto para el tratamiento de enfermedades o trastornos relacionados con el receptor de histamina h3.
ATE400567T1 (de) Kinaseinhibitoren
EA201170617A1 (ru) Пиразолиламинопиридины в качестве ингибиторов fak
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
NO20082096L (no) Azaindol-2-karboksamidderivativer